NCT00422019View on ClinicalTrials.gov

A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Advanced Renal Cell Carcinoma
Interventions
DRUG

AMG 102 at 10 mg/kg

AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks

DRUG

AMG 102 at 20 mg/kg

AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY